Kellmeyer previously served as the company’s Senior Vice President of Clinical Development and currently acts as a senior advisor.
Methinks she objected to Missling's trial plans over the years as inadequate, so stepped out as SVP of clinical development. She sounds like the right person to get proper trials going ASAP